-
1
-
-
84924271853
-
Global cancer statistics, 2012
-
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
-
(2015)
CA Cancer J Clin
, vol.65
, Issue.2
, pp. 87-108
-
-
Torre, L.A.1
Bray, F.2
Siegel, R.L.3
Ferlay, J.4
Lortet-Tieulent, J.5
Jemal, A.6
-
2
-
-
0034680102
-
Molecular portraits of human breast tumours
-
Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
-
(2000)
Nature
, vol.406
, Issue.6797
, pp. 747-752
-
-
Perou, C.M.1
Sørlie, T.2
Eisen, M.B.3
-
3
-
-
0035845511
-
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
-
Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-10874.
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
, Issue.19
, pp. 10869-10874
-
-
Sørlie, T.1
Perou, C.M.2
Tibshirani, R.3
-
4
-
-
69449090120
-
Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
-
Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20(8):1319-1329.
-
(2009)
Ann Oncol
, vol.20
, Issue.8
, pp. 1319-1329
-
-
Goldhirsch, A.1
Ingle, J.N.2
Gelber, R.D.3
Coates, A.S.4
Thürlimann, B.5
Senn, H.J.6
-
5
-
-
33846568336
-
American Society of Clinical Oncology/College of American Pathologists guideline recom-mendations for human epidermal growth factor receptor 2 testing in breast cancer
-
Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recom-mendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18-43.
-
(2007)
Arch Pathol Lab Med
, vol.131
, Issue.1
, pp. 18-43
-
-
Wolff, A.C.1
Hammond, M.E.2
Schwartz, J.N.3
-
6
-
-
34547661993
-
Triple-negative breast cancer: Clinical features and patterns of recurrence
-
Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429-4434.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.15
, pp. 4429-4434
-
-
Dent, R.1
Trudeau, M.2
Pritchard, K.I.3
-
7
-
-
56949103031
-
What is triple-negative breast cancer?
-
Irvin WJ Jr, Carey LA. What is triple-negative breast cancer? Eur J Cancer. 2008;44(18):2799-2805.
-
(2008)
Eur J Cancer
, vol.44
, Issue.18
, pp. 2799-2805
-
-
Irvin, W.J.1
Carey, L.A.2
-
8
-
-
55849132481
-
Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: High incidence of central nervous system metastases
-
Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638-2645.
-
(2008)
Cancer
, vol.113
, Issue.10
, pp. 2638-2645
-
-
Lin, N.U.1
Claus, E.2
Sohl, J.3
Razzak, A.R.4
Arnaout, A.5
Winer, E.P.6
-
9
-
-
4143150688
-
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
-
Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367-5374.
-
(2004)
Clin Cancer Res
, vol.10
, Issue.16
, pp. 5367-5374
-
-
Nielsen, T.O.1
Hsu, F.D.2
Jensen, K.3
-
10
-
-
45149094267
-
Basal-like breast cancer: A critical review
-
Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26(15):2568-2581.
-
(2008)
J Clin Oncol
, vol.26
, Issue.15
, pp. 2568-2581
-
-
Rakha, E.A.1
Reis-Filho, J.S.2
Ellis, I.O.3
-
11
-
-
37248999372
-
Triple negative tumours: A critical review
-
Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology. 2008;52(1):108-118.
-
(2008)
Histopathology
, vol.52
, Issue.1
, pp. 108-118
-
-
Reis-Filho, J.S.1
Tutt, A.N.2
-
13
-
-
34247569300
-
Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry
-
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109(9):1721-1728.
-
(2007)
Cancer
, vol.109
, Issue.9
, pp. 1721-1728
-
-
Bauer, K.R.1
Brown, M.2
Cress, R.D.3
Parise, C.A.4
Caggiano, V.5
-
14
-
-
33744960226
-
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
-
Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-2502.
-
(2006)
JAMA
, vol.295
, Issue.21
, pp. 2492-2502
-
-
Carey, L.A.1
Perou, C.M.2
Livasy, C.A.3
-
15
-
-
84856334753
-
Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design
-
Eiermann W, Bergh J, Cardoso F, et al. Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. Breast. 2012;21(1):20-26.
-
(2012)
Breast
, vol.21
, Issue.1
, pp. 20-26
-
-
Eiermann, W.1
Bergh, J.2
Cardoso, F.3
-
16
-
-
79952253747
-
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer
-
Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17(5):1082-1089.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.5
, pp. 1082-1089
-
-
Gonzalez-Angulo, A.M.1
Timms, K.M.2
Liu, S.3
-
17
-
-
84957708469
-
Genetic/familial high-risk assessment: Breast and ovarian, Version 2.2015
-
Daly MB, Pilarski R, Axilbund JE, et al. Genetic/familial high-risk assessment: breast and ovarian, Version 2.2015. J Natl Compr Canc Netw. 2016;14(2):153-162.
-
(2016)
J Natl Compr Canc Netw
, vol.14
, Issue.2
, pp. 153-162
-
-
Daly, M.B.1
Pilarski, R.2
Axilbund, J.E.3
-
18
-
-
41649102048
-
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
-
Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275-1281.
-
(2008)
J Clin Oncol
, vol.26
, Issue.8
, pp. 1275-1281
-
-
Liedtke, C.1
Mazouni, C.2
Hess, K.R.3
-
19
-
-
33847063053
-
The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
-
Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-2334.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.8
, pp. 2329-2334
-
-
Carey, L.A.1
Dees, E.C.2
Sawyer, L.3
-
20
-
-
84890283025
-
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes
-
Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232(2):142-150.
-
(2014)
J Pathol
, vol.232
, Issue.2
, pp. 142-150
-
-
Lehmann, B.D.1
Pietenpol, J.A.2
-
21
-
-
84872336069
-
Heterogeneity of triple-negative breast cancer: Histologic subtyping to inform the outcome
-
Montagna E, Maisonneuve P, Rotmensz N, et al. Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin Breast Cancer. 2013;13(1):31-39.
-
(2013)
Clin Breast Cancer
, vol.13
, Issue.1
, pp. 31-39
-
-
Montagna, E.1
Maisonneuve, P.2
Rotmensz, N.3
-
22
-
-
84859948408
-
Triple negative breast carcinoma: The good, the bad and the ugly
-
Kandil D, Khan A. Triple negative breast carcinoma: the good, the bad and the ugly. Diagn Histopathol (Oxf). 2012;18(5):210-216.
-
(2012)
Diagn Histopathol (Oxf)
, vol.18
, Issue.5
, pp. 210-216
-
-
Kandil, D.1
Khan, A.2
-
23
-
-
84877028141
-
Comprehensive molecular portraits of human breast tumours
-
Cancer Genome Atlas Networ
-
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
-
(2012)
Nature
, vol.490
, Issue.7418
, pp. 61-70
-
-
-
24
-
-
84862526929
-
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
-
Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395-399.
-
(2012)
Nature
, vol.486
, Issue.7403
, pp. 395-399
-
-
Shah, S.P.1
Roth, A.2
Goya, R.3
-
25
-
-
79960015997
-
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
-
Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-2767.
-
(2011)
J Clin Invest
, vol.121
, Issue.7
, pp. 2750-2767
-
-
Lehmann, B.D.1
Bauer, J.A.2
Chen, X.3
-
26
-
-
34548863946
-
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors
-
Herschkowitz JI, Simin K, Weigman VJ, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007;8(5):R76.
-
(2007)
Genome Biol
, vol.8
, Issue.5
, pp. 76
-
-
Herschkowitz, J.I.1
Simin, K.2
Weigman, V.J.3
-
27
-
-
78049308800
-
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
-
Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12(5):R68.
-
(2010)
Breast Cancer Res
, vol.12
, Issue.5
, pp. 68
-
-
Prat, A.1
Parker, J.S.2
Karginova, O.3
-
28
-
-
84927621560
-
Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer
-
Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688-1698.
-
(2015)
Clin Cancer Res
, vol.21
, Issue.7
, pp. 1688-1698
-
-
Burstein, M.D.1
Tsimelzon, A.2
Poage, G.M.3
-
29
-
-
84886412350
-
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes
-
Masuda H, Baggerly KA, Wang Y, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19(19):5533-5540.
-
(2013)
Clin Cancer Res
, vol.19
, Issue.19
, pp. 5533-5540
-
-
Masuda, H.1
Baggerly, K.A.2
Wang, Y.3
-
30
-
-
0035902108
-
Genome maintenance mechanisms for preventing cancer
-
Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411(6835):366-374.
-
(2001)
Nature
, vol.411
, Issue.6835
, pp. 366-374
-
-
Hoeijmakers, J.H.1
-
31
-
-
0027973206
-
DNA repair: Incisions for excision
-
Hoeijmakers JH, Bootsma D. DNA repair: incisions for excision. Nature. 1994;371(6499):654-655.
-
(1994)
Nature
, vol.371
, Issue.6499
, pp. 654-655
-
-
Hoeijmakers, J.H.1
Bootsma, D.2
-
32
-
-
0037169354
-
Cancer susceptibility and the functions of BRCA1 and BRCA2
-
Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108(2):171-182.
-
(2002)
Cell
, vol.108
, Issue.2
, pp. 171-182
-
-
Venkitaraman, A.R.1
-
33
-
-
84863994288
-
Dissecting the heterogeneity of triple-negative breast cancer
-
Metzger-Filho O, Tutt A, de Azambuja E, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol. 2012;30(15):1879-1887.
-
(2012)
J Clin Oncol
, vol.30
, Issue.15
, pp. 1879-1887
-
-
Metzger-Filho, O.1
Tutt, A.2
De Azambuja, E.3
-
34
-
-
33749022506
-
Basal-like breast cancer and the BRCA1 phenotype
-
Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25(43):5846-5853.
-
(2006)
Oncogene
, vol.25
, Issue.43
, pp. 5846-5853
-
-
Turner, N.C.1
Reis-Filho, J.S.2
-
35
-
-
4944229642
-
Hallmarks of ‘BRCAness’ in sporadic cancers
-
Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 2004;4(10):814-819.
-
(2004)
Nat Rev Cancer
, vol.4
, Issue.10
, pp. 814-819
-
-
Turner, N.1
Tutt, A.2
Ashworth, A.3
-
36
-
-
84878594500
-
Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
-
Lips EH, Mulder L, Oonk A, et al. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer. 2013;108(10):2172-2177.
-
(2013)
Br J Cancer
, vol.108
, Issue.10
, pp. 2172-2177
-
-
Lips, E.H.1
Mulder, L.2
Oonk, A.3
-
37
-
-
40849139208
-
Epigenetics in cancer
-
Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11):1148-1159.
-
(2008)
N Engl J Med
, vol.358
, Issue.11
, pp. 1148-1159
-
-
Esteller, M.1
-
38
-
-
0034607234
-
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors
-
Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92(7):564-569.
-
(2000)
J Natl Cancer Inst
, vol.92
, Issue.7
, pp. 564-569
-
-
Esteller, M.1
Silva, J.M.2
Dominguez, G.3
-
39
-
-
84908406633
-
Applying synthetic lethality for the selective targeting of cancer
-
McLornan DP, List A, Mufti GJ. Applying synthetic lethality for the selective targeting of cancer. N Engl J Med. 2014;371(18):1725-1735.
-
(2014)
N Engl J Med
, vol.371
, Issue.18
, pp. 1725-1735
-
-
McLornan, D.P.1
List, A.2
Mufti, G.J.3
-
40
-
-
84937107044
-
Challenges in the use of DNA repair deficiency as a biomarker in breast cancer
-
Schouten PC, Linn SC. Challenges in the use of DNA repair deficiency as a biomarker in breast cancer. J Clin Oncol. 2015;33(17):1867-1869.
-
(2015)
J Clin Oncol
, vol.33
, Issue.17
, pp. 1867-1869
-
-
Schouten, P.C.1
Linn, S.C.2
-
41
-
-
84901664854
-
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
-
Watkins JA, Irshad S, Grigoriadis A, Tutt AN. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 2014;16(3):211.
-
(2014)
Breast Cancer Res
, vol.16
, Issue.3
, pp. 211
-
-
Watkins, J.A.1
Irshad, S.2
Grigoriadis, A.3
Tutt, A.N.4
-
42
-
-
84924259541
-
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
-
Timms KM, Abkevich V, Hughes E, et al. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 2014;16(6):475.
-
(2014)
Breast Cancer Res
, vol.16
, Issue.6
, pp. 475
-
-
Timms, K.M.1
Abkevich, V.2
Hughes, E.3
-
43
-
-
0024367232
-
Cisplatin in the management of breast cancer
-
Sledge GW Jr, Roth BJ. Cisplatin in the management of breast cancer. Semin Oncol. 1989;16(4 Suppl 6):110-115.
-
(1989)
Semin Oncol
, vol.16
, Issue.4
, pp. 110-115
-
-
Sledge, G.W.1
Roth, B.J.2
-
44
-
-
54949097426
-
Platinum-based chemotherapy in triple-negative breast cancer
-
Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol. 2008;19(11):1847-1852.
-
(2008)
Ann Oncol
, vol.19
, Issue.11
, pp. 1847-1852
-
-
Sirohi, B.1
Arnedos, M.2
Popat, S.3
-
45
-
-
79953313824
-
Platinum-based chemotherapy in metastatic triple-negative breast cancer: The Institut Curie experience
-
Staudacher L, Cottu PH, Diéras V, et al. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol. 2011;22(4):848-856.
-
(2011)
Ann Oncol
, vol.22
, Issue.4
, pp. 848-856
-
-
Staudacher, L.1
Cottu, P.H.2
Diéras, V.3
-
46
-
-
84937145516
-
TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer
-
Isakoff SJ, Mayer EL, He L, et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol. 2015;33(17):1902-1909.
-
(2015)
J Clin Oncol
, vol.33
, Issue.17
, pp. 1902-1909
-
-
Isakoff, S.J.1
Mayer, E.L.2
He, L.3
-
48
-
-
33847063053
-
The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
-
Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-2334.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.8
, pp. 2329-2334
-
-
Carey, L.A.1
Dees, E.C.2
Sawyer, L.3
-
49
-
-
84904188903
-
Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis
-
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-172.
-
(2014)
Lancet
, vol.384
, Issue.9938
, pp. 164-172
-
-
Cortazar, P.1
Zhang, L.2
Untch, M.3
-
50
-
-
75749143502
-
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy
-
Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28(3):375-379.
-
(2010)
J Clin Oncol
, vol.28
, Issue.3
, pp. 375-379
-
-
Byrski, T.1
Gronwald, J.2
Huzarski, T.3
-
51
-
-
84919696970
-
Carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer - A phase II clinical trial
-
Zhang P, Yin Y, Xu B, et al. Carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer - a phase II clinical trial. Cancer Res. 2013;73:P3-14-07.
-
(2013)
Cancer Res
, vol.73
-
-
Zhang, P.1
Yin, Y.2
Xu, B.3
-
52
-
-
84901587677
-
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial
-
von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet. 2014;15(7):747-756.
-
(2014)
Lancet
, vol.15
, Issue.7
, pp. 747-756
-
-
Von Minckwitz, G.1
Schneeweiss, A.2
Loibl, S.3
-
53
-
-
84920569142
-
Impact of the addition of carboplatin and-or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin an cyclophosphamide on pathologic complete response rates in stages II to III triple negative breast cancer: CALGB 40603 (Alliance)
-
Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and-or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin an cyclophosphamide on pathologic complete response rates in stages II to III triple negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33(1):13-21.
-
(2015)
J Clin Oncol
, vol.33
, Issue.1
, pp. 13-21
-
-
Sikov, W.M.1
Berry, D.A.2
Perou, C.M.3
-
54
-
-
84868204484
-
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting: Results from the GEICAM/2006-03, multicenter study
-
Alba E, Chacon JI, Lluch A, et al. A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting: results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat. 2012;136(2):487-493.
-
(2012)
Breast Cancer Res Treat
, vol.136
, Issue.2
, pp. 487-493
-
-
Alba, E.1
Chacon, J.I.2
Lluch, A.3
-
56
-
-
84975254348
-
Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)
-
von Minckwitz G, Loibl S, Schneeweiss A, et al. Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Cancer Res. 2016;76:S2-S4.
-
(2016)
Cancer Res
, vol.76
, pp. S2-S4
-
-
Von Minckwitz, G.1
Loibl, S.2
Schneeweiss, A.3
-
58
-
-
84939423024
-
Tailoring therapies - Improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
-
Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies - improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533-1546.
-
(2015)
Ann Oncol
, vol.26
, Issue.8
, pp. 1533-1546
-
-
Coates, A.S.1
Winer, E.P.2
Goldhirsch, A.3
-
59
-
-
84975219187
-
-
Accessed January 1, 201
-
Fasching PA, Loibl S, Eidtmann H, et al. BRCA mutations, therapy response and prognosis in the neoadjuvant GeparQuinto study. 2015. Available from: http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_822&terms=. Accessed January 1, 2016.
-
(2015)
BRCA Mutations, Therapy Response and Prognosis in the Neoadjuvant Geparquinto Study
-
-
Fasching, P.A.1
Loibl, S.2
Eidtmann, H.3
-
60
-
-
67650471685
-
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
-
Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123-134.
-
(2009)
N Engl J Med
, vol.361
, Issue.2
, pp. 123-134
-
-
Fong, P.C.1
Boss, D.S.2
Yap, T.A.3
-
61
-
-
77955019276
-
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial
-
Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235-244.
-
(2010)
Lancet
, vol.376
, Issue.9737
, pp. 235-244
-
-
Tutt, A.1
Robson, M.2
Garber, J.E.3
-
62
-
-
84921771510
-
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
-
Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244-250.
-
(2015)
J Clin Oncol
, vol.33
, Issue.3
, pp. 244-250
-
-
Kaufman, B.1
Shapira-Frommer, R.2
Schmutzler, R.K.3
-
63
-
-
80052389761
-
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study
-
Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852-861.
-
(2011)
Lancet Oncol
, vol.12
, Issue.9
, pp. 852-861
-
-
Gelmon, K.A.1
Tischkowitz, M.2
Mackay, H.3
-
64
-
-
84925270121
-
An update on PARP inhibitors - Moving to the adjuvant setting
-
Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M. An update on PARP inhibitors - moving to the adjuvant setting. Nat Rev Clin Oncol. 2015;12(1):27-41.
-
(2015)
Nat Rev Clin Oncol
, vol.12
, Issue.1
, pp. 27-41
-
-
Sonnenblick, A.1
De Azambuja, E.2
Azim, H.A.3
Piccart, M.4
-
65
-
-
76349117455
-
Androgen receptor in breast cancer: Expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation
-
Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 2010;23(2):205-212.
-
(2010)
Mod Pathol
, vol.23
, Issue.2
, pp. 205-212
-
-
Niemeier, L.A.1
Dabbs, D.J.2
Beriwal, S.3
Striebel, J.M.4
Bhargava, R.5
-
66
-
-
84946493131
-
Androgen receptor biology in triple negative breast cancer: A case for classification as AR+ or quadruple negative disease
-
Barton VN, D’Amato NC, Gordon MA, Christenson JL, Elias A, Richer JK. Androgen receptor biology in triple negative breast cancer: a case for classification as AR+ or quadruple negative disease. Horm Cancer. 2015;6(5-6):206-213.
-
(2015)
Horm Cancer
, vol.6
, Issue.5-6
, pp. 206-213
-
-
Barton, V.N.1
D’Amato, N.C.2
Gordon, M.A.3
Christenson, J.L.4
Elias, A.5
Richer, J.K.6
-
67
-
-
84937041191
-
Targeting the androgen receptor in prostate and breast cancer: Several new agents in development
-
Proverbs-Singh T, Feldman JL, Morris MJ, Autio KA, Traina TA. Targeting the androgen receptor in prostate and breast cancer: several new agents in development. Endocr Relat Cancer. 2015;22(3):R87-R106.
-
(2015)
Endocr Relat Cancer
, vol.22
, Issue.3
, pp. R87-R106
-
-
Proverbs-Singh, T.1
Feldman, J.L.2
Morris, M.J.3
Autio, K.A.4
Traina, T.A.5
-
68
-
-
22744448864
-
Identification of molecular apocrine breast tumours by microarray analysis
-
Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24(29):4660-4671.
-
(2005)
Oncogene
, vol.24
, Issue.29
, pp. 4660-4671
-
-
Farmer, P.1
Bonnefoi, H.2
Becette, V.3
-
69
-
-
33745603978
-
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen
-
Doane AS, Danso M, Lal P, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006;25(28):3994-4008.
-
(2006)
Oncogene
, vol.25
, Issue.28
, pp. 3994-4008
-
-
Doane, A.S.1
Danso, M.2
Lal, P.3
-
70
-
-
84886425456
-
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer
-
Gucalp A, Tolaney S, Isakoff SJ, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res. 2013;19(19):5505-5512.
-
(2013)
Clin Cancer Res
, vol.19
, Issue.19
, pp. 5505-5512
-
-
Gucalp, A.1
Tolaney, S.2
Isakoff, S.J.3
-
71
-
-
84975316497
-
Abstract P5-19-09: Preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)
-
Traina TA, O’Shaughnessy J, Nanda R, et al. Abstract P5-19-09: preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). Cancer Res. 2015;75:P5-19-09.
-
(2015)
Cancer Res
, vol.75
-
-
Traina, T.A.1
O’Shaughnessy, J.2
Nanda, R.3
-
72
-
-
84940467449
-
Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)
-
Traina TA, Miller K, Yardley DA, et al. Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). J Clin Oncol., 2015;(33 Suppl):1003.
-
(2015)
J Clin Oncol
, Issue.33
, pp. 1003
-
-
Traina, T.A.1
Miller, K.2
Yardley, D.A.3
-
73
-
-
84955440805
-
Complete response of metastatic androgen receptor-positive breast cancer to bicalutamide: Case report and review of the literature
-
Arce-Salinas C, Riesco-Martinez MC, Hanna W, Bedard PH, Warner E. Complete response of metastatic androgen receptor-positive breast cancer to bicalutamide: case report and review of the literature. J Clin Oncol. 2016;34(4):e21-e24.
-
(2016)
J Clin Oncol
, vol.34
, Issue.4
, pp. e21-e24
-
-
Arce-Salinas, C.1
Riesco-Martinez, M.C.2
Hanna, W.3
Bedard, P.H.4
Warner, E.5
-
74
-
-
84937643430
-
Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?
-
Anestis A, Karamouzis MV, Dalagiorgou G, Papavassiliou AG. Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer? Cancer Treat Rev. 2015;41(6):547-553.
-
(2015)
Cancer Treat Rev
, vol.41
, Issue.6
, pp. 547-553
-
-
Anestis, A.1
Karamouzis, M.V.2
Dalagiorgou, G.3
Papavassiliou, A.G.4
-
75
-
-
84886945668
-
Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy
-
Loi S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunology. 2013;2(7):e24720.
-
(2013)
Oncoimmunology
, vol.2
, Issue.7
-
-
Loi, S.1
-
76
-
-
84905178989
-
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial
-
Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8):1544-1550.
-
(2014)
Ann Oncol
, vol.25
, Issue.8
, pp. 1544-1550
-
-
Loi, S.1
Michiels, S.2
Salgado, R.3
-
77
-
-
84912011347
-
The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: A meta-analysis
-
Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, Kazkaz GA. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. Breast Cancer Res Treat. 2014;148(3):467-476.
-
(2014)
Breast Cancer Res Treat
, vol.148
, Issue.3
, pp. 467-476
-
-
Ibrahim, E.M.1
Al-Foheidi, M.E.2
Al-Mansour, M.M.3
Kazkaz, G.A.4
-
78
-
-
84907198355
-
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199
-
Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959-2966.
-
(2014)
J Clin Oncol
, vol.32
, Issue.27
, pp. 2959-2966
-
-
Adams, S.1
Gray, R.J.2
Demaria, S.3
-
79
-
-
84875722651
-
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98
-
Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860-867.
-
(2013)
J Clin Oncol
, vol.31
, Issue.7
, pp. 860-867
-
-
Loi, S.1
Sirtaine, N.2
Piette, F.3
-
80
-
-
84865191854
-
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
-
Ono M, Tsuda H, Shimizu C, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012;132(3):793-805.
-
(2012)
Breast Cancer Res Treat
, vol.132
, Issue.3
, pp. 793-805
-
-
Ono, M.1
Tsuda, H.2
Shimizu, C.3
-
81
-
-
73949092850
-
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer
-
Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105-113.
-
(2010)
J Clin Oncol
, vol.28
, Issue.1
, pp. 105-113
-
-
Denkert, C.1
Loibl, S.2
Noske, A.3
-
82
-
-
84927138902
-
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers
-
Denkert C, von MG, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983-991.
-
(2015)
J Clin Oncol
, vol.33
, Issue.9
, pp. 983-991
-
-
Denkert, C.1
Von, M.G.2
Brase, J.C.3
-
83
-
-
79959243434
-
Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes
-
Smid M, Hoes M, Sieuwerts AM, et al. Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. Breast Cancer Res Treat. 2011;128(1):23-30.
-
(2011)
Breast Cancer Res Treat
, vol.128
, Issue.1
, pp. 23-30
-
-
Smid, M.1
Hoes, M.2
Sieuwerts, A.M.3
-
84
-
-
84927150740
-
Immune checkpoint blockade in cancer therapy
-
Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974-1982.
-
(2015)
J Clin Oncol
, vol.33
, Issue.17
, pp. 1974-1982
-
-
Postow, M.A.1
Callahan, M.K.2
Wolchok, J.D.3
-
85
-
-
84928760665
-
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
-
Homet MB, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer. 2015;112(9):1421-1427.
-
(2015)
Br J Cancer
, vol.112
, Issue.9
, pp. 1421-1427
-
-
Homet, M.B.1
Ribas, A.2
-
86
-
-
84919385463
-
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type
-
Gatalica Z, Snyder C, Maney T, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2965-2970.
-
(2014)
Cancer Epidemiol Biomarkers Prev
, vol.23
, Issue.12
, pp. 2965-2970
-
-
Gatalica, Z.1
Snyder, C.2
Maney, T.3
-
88
-
-
84937961692
-
Abstract S1-09: A phase IB study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
-
Nanda R, Chow LQ, Dees EC, et al. Abstract S1-09: a phase IB study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Cancer Res. 2015;75:S1-S9.
-
(2015)
Cancer Res
, vol.75
, pp. S1-S9
-
-
Nanda, R.1
Chow, L.Q.2
Dees, E.C.3
-
89
-
-
84944041240
-
Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer
-
Emens LA, Braiteh FS, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. Cancer Res. 2015;75:PD1-PD6.
-
(2015)
Cancer Res
, vol.75
, pp. PD1-PD6
-
-
Emens, L.A.1
Braiteh, F.S.2
Cassier, P.3
-
90
-
-
85010223314
-
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase IB JAVELIN solid tumor trial
-
Dirix LY, Takacs I, Nikolinakos P, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase IB JAVELIN solid tumor trial. Cancer Res. 2016;76:S1-S4.
-
(2016)
Cancer Res
, vol.76
, pp. S1-S4
-
-
Dirix, L.Y.1
Takacs, I.2
Nikolinakos, P.3
-
91
-
-
84927142845
-
Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer
-
Tung NM, Winer EP. Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer. J Clin Oncol. 2015;33(9):969-971.
-
(2015)
J Clin Oncol
, vol.33
, Issue.9
, pp. 969-971
-
-
Tung, N.M.1
Winer, E.P.2
-
93
-
-
84883050174
-
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): Primary results of a randomised, phase 3 trial
-
Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013;14(10):933-942.
-
(2013)
Lancet Oncol
, vol.14
, Issue.10
, pp. 933-942
-
-
Cameron, D.1
Brown, J.2
Dent, R.3
-
94
-
-
84860389233
-
Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: Possible implications for targeted therapy
-
Teng YH, Tan WJ, Thike AA, et al. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res. 2011;13(2):R35.
-
(2011)
Breast Cancer Res
, vol.13
, Issue.2
, pp. 35
-
-
Teng, Y.H.1
Tan, W.J.2
Thike, A.A.3
-
95
-
-
84868208974
-
Role of epidermal growth factor receptor in breast cancer
-
Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012;136(2):331-345.
-
(2012)
Breast Cancer Res Treat
, vol.136
, Issue.2
, pp. 331-345
-
-
Masuda, H.1
Zhang, D.2
Bartholomeusz, C.3
Doihara, H.4
Hortobagyi, G.N.5
Ueno, N.T.6
-
96
-
-
84864101306
-
TBCRC 001: Randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer
-
Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30(21):2615-2623.
-
(2012)
J Clin Oncol
, vol.30
, Issue.21
, pp. 2615-2623
-
-
Carey, L.A.1
Rugo, H.S.2
Marcom, P.K.3
-
97
-
-
75149170979
-
Fibroblast growth factor signalling: From development to cancer
-
Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116-129.
-
(2010)
Nat Rev Cancer
, vol.10
, Issue.2
, pp. 116-129
-
-
Turner, N.1
Grose, R.2
-
98
-
-
79959713140
-
Fibroblast growth factors and their receptors in cancer
-
Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J. 2011;437(2):199-213.
-
(2011)
Biochem J
, vol.437
, Issue.2
, pp. 199-213
-
-
Wesche, J.1
Haglund, K.2
Haugsten, E.M.3
-
99
-
-
77950866696
-
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
-
Turner N, Lambros MB, Horlings HM, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 2010;29(14):2013-2023.
-
(2010)
Oncogene
, vol.29
, Issue.14
, pp. 2013-2023
-
-
Turner, N.1
Lambros, M.B.2
Horlings, H.M.3
-
100
-
-
84946958389
-
A phase 2, randomized, open-label, multicenter, safety and efficacy study of oral lucitanib in patients with metastatic breast cancer with alterations in the FGF pathway
-
Abu-Khalaf MM, Mayer IA, Litten JB, et al. A phase 2, randomized, open-label, multicenter, safety and efficacy study of oral lucitanib in patients with metastatic breast cancer with alterations in the FGF pathway. Cancer Res. 2015;75:OT1-1-13.
-
(2015)
Cancer Res
, vol.75
-
-
Abu-Khalaf, M.M.1
Mayer, I.A.2
Litten, J.B.3
-
101
-
-
84955472185
-
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
-
Shu SK, Lin CY, He HS, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016;529(7586):413-417.
-
(2016)
Nature
, vol.529
, Issue.7586
, pp. 413-417
-
-
Shu, S.K.1
Lin, C.Y.2
He, H.S.3
|